Bank of the West’s RenovoRx RNXT Stock Holding History

Bank of the West’s Portfolio RNXT Stock Details RNXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$2.29M	Hold	975,000	–	–	0.27%	101
2022 Q3	$1.97M	Hold	975,000	–	–	0.26%	102
2022 Q2	$1.93M	Buy	+975,000	New	+$1.99M	0.24%	102

Other funds holding RNXT

LBC

Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

ACA

Affinity Capital Advisors Berkeley, California $810M AUM 24.85% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of the West's RNXT Position: Q4 2022 in Review

Bank of the West held its RenovoRx (RNXT) position steady in Q4 2022 at 975,000 shares worth $2.29M. The position accounts for 0.27% of the portfolio, ranked #101.

Bank of the West first reported a position in RNXT in Q2 2022 and has held it in 3 quarters since. 11 funds tracked by Wall St. Rank hold RNXT as of Q4 2022.

Bank of the West held 975,000 shares of RenovoRx worth $2.29M as of Q4 2022.
Bank of the West left its RenovoRx share count unchanged in Q4 2022.
RenovoRx made up 0.27% of Bank of the West's portfolio in Q4 2022, its #101 holding.
Bank of the West first reported a position in RenovoRx in Q2 2022 and has held it in 3 quarters since.
11 funds tracked by Wall St. Rank held RenovoRx as of Q4 2022.

Based on Bank of the West's 13F filing for Q4 2022, filed 1 Feb 2023.